Penicillin G Benzathine (Bicillin L-A) Injection Shortage: Latest Updates and Availability
According to the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates, the CDC PLACES population-level health analysis, and the CMS Hospital Compare quality data, Areazine publishes editorial articles drawing on more than 19,000 U.S. city profiles. See our methodology for full source attribution and refresh cadence.
The FDA reports a current shortage of Penicillin G Benzathine Injection (Bicillin L-A) due to manufacturing delays, with limited availability expected through late 2026.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on February 17, 2026 and geographically references United States. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — Drug Shortages — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, Penicillin-G-Benzathine) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What's in Shortage
Penicillin G Benzathine Injection, commonly known by the brand name BICILLIN L-A, is currently in shortage. This medication is classified as an Anti-Infective and is administered as an injection. The shortage was first reported on April 26, 2023, and the status was last updated on February 12, 2026.
Which Manufacturers Are Affected
Pfizer Inc. is the manufacturer currently experiencing supply issues. The status of specific presentations is as follows:
- Bicillin L-A, Injection, 600,000 [iU]/1 mL (NDC 60793-700-10): Currently Unavailable. The manufacturer estimates recovery by December 2026.
- Bicillin L-A, Injection, 1,200,000 [iU]/2 mL (NDC 60793-701-10): Currently under Limited Availability. The next delivery is expected in July 2026, with an estimated recovery date of December 2026.
- Bicillin L-A, Injection, 2,400,000 [iU]/4 mL (NDC 60793-702-10): Currently under Limited Availability. The next delivery is expected in July 2026, with an estimated recovery date of December 2026.
For more information, Pfizer Inc. can be contacted at 844-646-4398.
Why There's a Shortage
The manufacturer has cited manufacturing delays as the reason for the current shortage. The FDA database categorizes the reason as "Other."
What Patients Should Do
If you or a loved one depends on this medication, please take the following steps:
- Consult Your Healthcare Provider: Discuss the shortage with your doctor to understand how it may affect your treatment plan.
- Speak with Your Pharmacist: Pharmacists often have the most current information regarding local stock and can help navigate supply issues.
- Contact the Manufacturer: You may reach out to Pfizer Inc. at 844-646-4398 for specific questions regarding their supply timeline.
Disclaimer: Patients should always consult their healthcare provider for medical advice and treatment options. Do not alter your prescribed treatment without professional medical guidance.
Source
Attribution: FDA Drug Shortage Database
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.
What is this FDA drug-shortage notice about? ▾
Which agency issued this alert? ▾
How severe is this alert? ▾
What area is affected? ▾
Where can I find more Drug Shortages updates? ▾
Primary source data
EPA Outdoor Air Quality Data
Federal monitoring network — every measurement we report
AirNow (EPA / NOAA)
Real-time AQI for every monitored U.S. location
National Weather Service
Active watches, warnings, and advisories — NOAA
CDC Air Quality & Health
Health-impact reference behind every AQI category